Introduction
The worldwide prevalence of overweight and obesity is rapidly increasing, and this negatively impacts the health of humans (Flier, 2004) . Obese individuals are more likely than their lean counterparts to develop cardiovascular disease, type 2 diabetes mellitus, metabolic disorders, and some cancers (Flier, 2004) . Excessive fat accumulation reflects an imbalance between energy expenditure and caloric intake, which leads to an increase in the number and/or size of fat cells. Adipocytes can be enlarged by excessive lipid deposition or generated from precursor ones. The essential step of adipocyte differentiation is the commitment from preadipocytes to adipocytes.
Differentiation of preadipocyte into adipocyte is regulated by an elaborate network of transcription factors that coordinate expression of hundreds of genes responsible for fat-cell phenotype (Rosen and MacDougald, 2006; Rosen and Spiegelman, 2000) . Peroxisome proliferator-activated receptor gamma (PPARg) is considered a master regulator of adipogenesis among transcription factors in particular (Barak et al., 1999; Rosen et al., 1999; Tontonoz et al., 1994) . Without it, precursor cells are incapable of expressing any known aspect of the adipocyte phenotype (Zhang et al., 2004) . The CCAAT/enhancer-binding protein (C/EBP) family plays a vital role in promoting adipocyte differentiation. C/EBPb and C/EBPd are induced early during the differentiation of 3T3-L1 preadipocytes upon hormonal stimulation (Tanaka et al., 1997; Wu et al., 1996 Wu et al., , 1995 , which is followed by the induction of PPARg and C/ERPa. C/EBPa, whose expression is highest during later stages of differentiation, is induced by PPARg activation. Krox20 , sterolregulatory element-binding protein (SREBP)-1c (Kim et al., 1998a (Kim et al., , 1998b Kim and Spiegelman, 1996) , and Stat5 (Kawai et al., 2007; Meirhaeghe et al., 2003; Nanbu-Wakao et al., 2002) have also been shown to be important in adipogenesis.
Members of the Kruppel-like factor (KLF) family of zinc-finger transcription factors have recently been identified as key regulators of cell activity and have received intensive investigations in human health and disease (McConnell and Yang, 2010) . KLF is derived from the Drosophila protein ''kruppel'' (meaning ''cripple'') which shares homology of proteins to the DNA-binding domains. Drosophila embryos deficient in kruppel die with consequences of abnormal thoracic and abdominal segmentation and thus appeared ''crippled'' (Nusslein-Volhard and Wieschaus, 2003; Zuo et al., 1991) . The distinguishing feature of the KLF family is the presence of three highly conserved classical Cys2/His2 zinc fingers (Bieker, 2001; Dang et al., 2000b; Turner and Crossley, 1999) , a motif that is the most abundant in transcription factors and the second most abundant in the human genome (Bieker, 2001) . Zinc fingers 1 and 2 contain 23 residues, while the third finger has only 21 residues . These fingers are located at the carboxyl terminus of the protein and enable KLFs to bind to related GC-and CACCC-boxes of DNA (Bieker, 2001; Dang et al., 2000b; Pearson et al., 2008; Turner and Crossley, 1999) . In contrast to the zinc-finger regions, the non-DNA-binding regions are highly divergent, modulate transactivation and transrepression, and often mediate interaction with various co-regulators, giving KLFs unique tissue-specific roles (Pearson et al., 2009 ).
The first mammalian kruppel homolog, termed erythroid Kruppel-like factor (EKLF/KLF1), was identified in 1993 as a factor specifically expressed in the red blood cell lineage (Bieker, 1996; Miller and Bieker, 1993; Parkins et al., 1995) . With the first KLF isolation and identification, a new subfamily of Kruppel-like proteins, which has a total of 17 mammalian KLFs, has emerged. These factors have been shown to have important roles in a diverse array of cellular processes including hematopoiesis (Nuez et al., 1995; Parkins et al., 1995) , organ development (Wani et al., 1999b) , cardiac remodeling Shindo et al., 2002) , angiogenesis (Bhattacharya et al., 2005) , monocyte activation (Das et al., 2006; Feinberg et al., 2005) , neoplasia (Rowland et al., 2005; Wei et al., 2005) , gluconeogenesis , cell growth regulation (Black et al., 2001) , and endothelial cell function Sen-Banerjee et al., 2005) . In recent years, many members of KLF have been identified to be involved in both adipogenesis and lipogenesis. This review focuses on the role of the KLF family members as promoters or inhibitors in fat biology and also their role in brown adipocyte tissue (summarized in Table 1 ).
KLFs that promote adipogenesis

KLF15
Kruppel-like factor 15 (KLF15) is the first KLF found to be involved in adipogenesis (Uchida et al., 2000) , which is initially identified as a protein that binds to CLC-K1 promoter, a kidneyspecific CLC chloride channel, thus formerly designated kidney KLF (KKLF). Northern blot analysis shows KLF15 expression to be more abundant in adipose, muscle (heart, skeletal muscle, and aorta), kidney, and liver in mouse tissues (Uchida et al., 2000) .
KLF15 is increased maximally at Day 6 in 3T3-L1 preadipocytes differentiation (Mori et al., 2005) . The time course of KLF15 mRNA up-regulation during adipocyte differentiation is in the late phase of adipogenesis, about 4 days after the adipogenic stimulation, 2 days later than the initial expression of PPARg and aP2 mRNAs, which is similar to the pattern of C/EBPa mRNA. (Mori et al., 2005) . It is well known that most transcription factors affect adipogenesis by recruiting PPARg. It is interesting to seek out whether the effects of KLF15 in promoting adipocyte differentiation are also dependent on the induction of PPARg. Mori T and his coworkers found that overexpression of PPARg2 promoted nonadipocyte cell line-NIH3T3 cells adipogenesis without changing its KLF15 expression. The similar phenomenon was also observed in MEFs derived from PPARg-/-mice infected with retroviral vectors for PPARg2 (Mori et al., 2005) . These findings reveal that PPARg is a downstream effector in adipocyte differentiation induced by KLF15 and KLF15 regulates adipogenesis via PPARg expression. However, the potential binding sites of KLF15 to PPARg promoter have not yet been identified. Similar methods were applied to demonstrate that KLF15 also is a downstream effector of C/EBPb or C/EBPd in PPARg induction during adipocyte differentiation (Mori et al., 2005) .
In addition to PPARg, a canonical adipogenic inducer during adipogenesis, glucocorticoid receptor (GR) also plays critical role in KLF15 gene expression in adipogenesis. GR stimulation is a required step for in vitro adipogenesis (Ito et al., 2007) . GR inhibitor blocks human MSCs and MEFs adipogenesis and MEFs from either GR-deficient or GR-dimeried mice exhibited impaired differentiation upon adipogenic induction. KLF15 expression was increased during adipose differentiation and this induction was suppressed either by RU486, a GR inhibitor or GR dysfunction (Asada et al., 2010) .
KLF15 overexpression in adipocyte promotes adipocyte maturation and potentiates glucose transporter 4 (GLUT4) expression (Gray et al., 2002) , and its role in regulating glucose production via modulating enzymes involved in either gluconeogenesis or amino acid catabolism . Acetyl-CoA is an important intermediate in energy production through the fatty acid/cholesterol metabolic pathway and the citric acid cycle. Acetyl-coA Synthetase (AceCS) is an enzyme that catalyzes the production of acetyl-CoA from acetate and CoA. AceCS2 expression induced by fasting is contributed by KLF15 (Yamamoto et al., 2004) . Adrenomedullin, as a potent vasodilatory hormone produced by mature adipocytes, is increased in 3T3L1 adipocyte due to KLF15 knockdown by RNA interference (Nagare et al., 2009 ). Adipocyte-derived adrenomedullin plays a protective role in the development of hypertension, insulin resistance, and the complications of these conditions in obese patients (Paulmyer-Lacroix et al., 2006) .
Mice with diet-induced obesity (DIO) or genetic obesity (ob/ob) exhibit lower levels of KLF15 expression in adipose tissue compared with normal controls (Nagai et al., 2009 ). KLF15 deficiency mice are protected against high fat diet (HFD) induced insulin resistance (IR) (Sartoretto et al., 2008) and also exhibit severe hypoglycemia after an overnight fast . Recently, evidence from Haldar et al. (2012) suggests that there are energy and substrate flux abnormalities in KLF15-/-mice during exercise. These data put KLF15 as a central component in all three basic cellular nutrients: Glucose, Amino acids, and Lipids metabolism. It is thus reasonable to speculate that obesity-induced KLF15 down regulation in adipose tissue is related to the pathogenesis of obesity induced health disorders.
KLF5
KLF5, also known as BTEB2 or IKLF, was identified as a transcription factor for SMemb/non-muscle myosin heavy chain-B (NMHC-B) (Watanabe et al., 1999) , a molecular marker of smooth-muscle cells (Kuro-o et al., 1989; Manabe et al., 1997) . Normally, KLF5 expresses abundantly in developing blood vessels, but downregulates in adult vessels (Watanabe et al., 1999) . However, its expression is strongly upregulated in activated smooth-muscle cells or fibroblasts (myofibroblasts) in vascular lesions (Hoshino et al., 2000) . Mice with complete absence of KLF5 show embryonic lethality by day E8.5 (Shindo et al., 2002) due to defects in preimplantation embryo development (Ema et al., 2008) . Heterozygous KLF5 knockout mice are viable into adulthood, but exhibit a marked deficiency in white adipose tissue (WAT) development starting from day 3 after birth. Body weight and WAT mass are markedly reduced in KLF5( þ/ À) mice than in wild-type mice and greater numbers of smaller adipocytes are observed in KLF5(þ/ À ) WAT, which contain little or no lipid (Oishi et al., 2005) . When fed a HFD, KLF5(þ/ À) mice are better protected from HFD-induced weight gain than their wild-type littermates (Oishi et al., 2008) . These findings suggest that KLF5 plays a key role in adipogenesis.
In in-vitro adipogenesis, KLF5 is induced in the early stages of differentiation. The way to activate KLF5 is not well clarified, but at least overexpression of either C/EBPb or C/EBPd results in induction of KLF5 promoter activity, which leads to KLF5 activation. Transfected 3T3L1 preadipocyte with KLF5 dominantnegative mutant significantly reduces lipid accumulation and markedly suppresses PPARg and C/EBPa expressions. Similar effects are also observed during 3T3-L1 differentiation when knocked down by KLF5-siRNA (Oishi et al., 2005) . MEFs derived from KLF5(þ/ À ) mice exhibit severely impaired adipocyte differentiation and lower levels of PPARg and C/EBPa (Oishi et al., 2005) . Conversely, KLF5 overexpression spontaneously promotes adipocyte differentiation, accompanied by PPARg and C/EBPa upregulation, even without hormonal stimulation (Oishi et al., 2005) . Further studies demonstrate that KLF5 can directly bind to the endogenous PPARg promoter, stimulating modest PPARg promoter activity, and this effect can be enhanced in concert with C/EBPb and C/EBPd. These data indicate that KLF5 is downstream of C/EBPb and C/EBPd, but upstream of PPARg during adipocyte differentiation (Oishi et al., 2005) .
KLF4
KLF4, first isolated by encoding the zinc finger region of the immediate-early transcription factor zif/268, is a gut-enriched Kruppel-like factor (GKLF/ZIF) (Garrett-Sinha et al., 1996; Shields et al., 1996) . KLF4 is primarily expressed in postmitotic or differentiated cells of the skin and the gastrointestinal tract and possesses a variety of roles as differentiation-proliferation switchers and cell cycle regulators (Garrett-Sinha et al., 1996; Shields et al., 1996; Takahashi and Yamanaka, 2006; Yoon et al., 2003) . KLF4 expression can also be found in naive, quiescent B lymphocytes and is rapidly down-regulated upon mitogenic activation (Glynne et al., 2000) . KLF4 knockout mice die 12 h after birth due to defects in skin development, with a failure of normal basement membrane formation (Segre et al., 1999) .
In vitro, the expression of KLF4 is mainly in a growth-arrested state caused by serum deprivation, contact inhibition, DNA damage, or growth-inhibitory cytokines Zhang et al., 2000) . The reduced expression is observed in conditions related to increased proliferation, such as in neoplasm (Dang et al., 2000a; Shie et al., 2000) . During 3T3-L1 differentiation, KLF4 expression is an early-stage event, and the expression pattern is similar to that of the well-known transcription factors C/EBPb. By knocking down KLF4, 3T3-L1 cells produce significantly less lipid than the controls, as well as adipogenic regulators such as adipsin, aP2, and PPARg (Birsoy et al., 2008) , making KLF4 a regulator in modulating adipocyte formation.
KLF4 regulates adipogenesis through transactivated C/EBPb by directly binding to its promoter at the critical region between À1.438 kb and À1.134 kb, although a clear consensus sequence remains to be identified. Krox20, known as a transcription factor, also transactivates C/EBPb promoter via sequences between À1.45 kb and À 1.1 kb . Krox20 and KLF4 can bind to one another and activate C/EBPb as coactivators, thereby overexpression of both Krox20 and C/EBPb can partially overcome KLF4 knockdown (Birsoy et al., 2008) . As the expression patterns of C/EBPb, Krox20, and KLF4 are similar, further exploration finds that C/EBPb deficient cells show increasing Krox20 and KLF4 levels, while C/EBPb overexpression exhibits a strongly decrease in KLF4, and to a lesser extent in Krox20 expression, indicating a potential negative feedback mechanism (Birsoy et al., 2008) . Notably, once aP2 promoter turns on, KLF4 expression may not be required at later stage of adipogenesis.
KLF6
KLF6 is originally identified as a quickly induced gene following hepatic stellate cells activation (Koritschoner et al., 1997; Lalazar et al., 1997; Ratziu et al., 1998; Suzuki et al., 1998) . It is also a novel tumor suppressor gene frequently mutated in human prostate and colon cancers (Narla et al., 2001; Reeves et al., 2004) , which is mainly through transcriptional up-regulation of p21waf1/cdi. Transcriptional targets of KLF6 include transforming growth factor-b1(TGFb1) and its receptors (TGFb1R) (Kim et al., 1998c) , urokinase-type plasminogen activator(uPA) (Kojima et al., 2000) , and the human immunodeficiency virus-long terminal repeat (HIV-LTR) (Suzuki et al., 1998) .
As to adipogenesis, KLF6 promotes preadipocyte differentiation by repressing a factor named Delta-like1 (Dlk1). Dlk1, a key regulator of adipogenesis, also known as preadipocyte factor-1 (pref-1), has a function to prevent 3T3-L1 preadipocytes differentiation through its sustained expression (Smas and Sul, 1993) . The dramatic down-regulation of Dlk1 after hormonal stimulation in preadipocytes is an early and necessary event in the fat cells phenotypic conversion. Dlk1 expressions in both NIH3T3 cells and 3T3-L1 preadipocytes are remarkably suppressed by stably transfected with KLF6. KLF6's induction occurs on day 0 after hormonal stimulation (Inuzuka et al., 1999; Li et al., 2005) via transcriptionally repressing Dlk1 expression and thereby promotes 3T3-L1 differentiation. The precise mechanism of KLF6 is that it can directly bind to the GC element in Dlk1 promoter (Li et al., 2005) , which is enhanced by interacting with HDAC3, a member of the class I Rpd 3-like histone deacetylases (Fajas et al., 2002) . HDAC3 acts as a corepressor of KLF6, and HDAC3 can interact directly with KLF6 without any other accessory factor to form a stable complex to repress Dlk1 expression (Li et al., 2005) . However, the direct role for KLF6 in adipocyte differentiation has not been reported to date, and future efforts should be made to explore its function in adipogenesis.
KLF9
KLF9 is a new member of KLF family involved in adipogenesis, which is previously designated as basic transcription elementbinding protein-1 (BTEB1) (Imataka et al., 1992) . The functions of KLF9 in many biological processes have been found. KLF9 regulates the transactivation of progesterone-responsive promoters and has been found to be downregulated in endometrial carcinoma and colorectal cancer (Kang et al., 2008; Simmen et al., 2008 Simmen et al., , 2010 . Mice lacking KLF9 show impairments in motor learning, motor coordination and fear-conditioning (Morita et al., 2003) . Increased expression of KLF9 in a human endometrial carcinoma cells leads to serum-dependent proliferation (Zhang et al., 2001) . KLF9 is also shown to regulate crypt-villus cell renewal in mice (Simmen et al., 2007) and secondary antibody responses of human splenic B cells (Good and Tangye, 2007) .
Induction of KLF9 during adipogenesis appears at the middle stage of differentiation and gradually increases throughout the middle and late stages. KLF9 expression pattern in 3T3-L1 cells is similar to that of previously reported late transcription factors for adipogenesis such as PPARg and C/EBPa, but different from that of early transcription factors such as C/EBPb or C/EBPd (Pei et al., 2010) . Notably, KLF9 can be directly activated by glucocorticoid stimulation during adipogenesis (Asada et al., 2010) , although further study is needed to verify it. The role of KLF9 to promote adipocyte differentiation has been well discussed. Knockdown KLF9 with siRNA suppresses a variety of adipogenic genes expression, including PPARg, C/EBPa and aP2, as well as adipocyte differentiation, whereas overexpression of KLF9 does not upregulate C/EBPa or PPARg levels (Pei et al., 2010) . KLF9 is required in adipogenesis, but its expression is not sufficient to perform a full process of adipocyte differentiation, and it needs to interact with accessorial factors. KLF9 promotes differentiation by binding to the PPARg2 promoter in À 413 to À 247 region directly and transactivating PPARg2 activity, and this effect is more significant in concert with C/EBPa through their physical interaction (Pei et al., 2010) .
KLFs that inhibit adipogenesis
KLF2
KLF2 is highly expressed in the lung with limited distribution in other organs, initially identified through a homology screening strategy using the zinc finger domain of KLF1 (Anderson et al., 1995; Wani et al., 1999a) . KLF2 plays a vital role in the development of the lung (Wani et al., 1999b) . Targeted deletion of KLF2 resulted in mice death around 12.5 days of gestation due to abnormal blood vessel development which forms severe hemorrhage, indicating an essential role in embryonic development (Kuo et al., 1997; Wani et al., 1998) .
KLF2 is highly expressed in both human and 3T3-L1 preadipocytes, and dramatically diminish upon adipocyte differentiation as significantly downregulate KLF2 promoter activity (Banerjee et al., 2003; Lee et al., 2010a; Wu et al., 2005) . Overexpression of KLF2 in 3T3-L1 cells shows a decrease in intracellular lipid accumulation as well as in transcription factors induction of PPARg, ADD1/SREBP1c and C/EBPa but not C/EBPb or C/EBPd (Banerjee et al., 2003) . The consequence of excess KLF2 expression blocks preadipocyte differentiation into adipocyte. By using tetresponse 3T3-L1 cell lines, Wu J and his coworker found that physiological level re-expression of KLF2 prevents preadipocyte differentiation partially through DLK1 restoration (Wu et al., 2005) , which seems like an opposite effect to KLF6 but needs more further study. KLF2 does not affect the commitment of pluripotent stem cells into the preadipocytic lineage. MEFs derived from KLF2 null mouse embryos retain the ability to differentiate efficiently into adipocytes upon adipogenic stimulation and are even more prone to initiate differentiation at the early stage (Wu et al., 2005) , illustrating that KLF2 exhibits as a natural repressor in preadipocyte differentiation.
To date, a series of experiments has been conducted to explore the mechanism of KLF2 pathway. KLF2 exerts its repression during adipogenesis through binding to PPARg2 promoter directly and inhibits the promoter activity (Banerjee et al., 2003) . However, the mutation of the kruppel binding site of PPARg2 promoter alone is not sufficient to completely abrogate KLF2-mediated inhibition of promoter activity, suggesting that non-DNA bindingdependent mechanisms are probably involved for the full inhibitory effect (Banerjee et al., 2003) . Furthermore, study from human adipose tissue derived mesenchymal stem cells shows that ultraviolet A inhibits adipogenic differentiation by KLF2 induction, which is mediated by migration inhibitory factor (MIF)-AMPK signaling (Lee et al., 2010b ).
KLF3
KLF3 is most highly expressed in erythroid cells, and other tissues most notably in the midbrain region of embryonic mice, also known as basic kruppel-like factor (BKLF) (Crossley et al., 1996) . KLF3 plays a role in hematopoiesis, as KLF3 deficient mice suffer from a myeloproliferative disorder (Funnell et al., 2007; Turner and Crossley, 1999) . Previous study also demonstrated that KLF3 expression is associated with B cell transformation (Pearson et al., 2011) .
Size and body weight of KLF3 null mice are significantly smaller than both their wild-type and heterozygous counterparts by the time of weaning (Sue et al., 2008) . Histological sections and the total DNA content of epididymal fat pads suggest smaller and fewer cells in fat pats in homozygous KLF3 deletion mice (Sue et al., 2008) .
However, in vitro cell culture shows an opposite results. KLF3 is abundant in 3T3-L1 preadipocyte and decreases markedly upon adipogenic stimulation. The time course of KLF3 expression is the same to that of KLF2, suggesting that their function may be similar. Overexpression of KLF3 by a retroviral system shows an inhibition in 3T3-L1 preadipocyte differentiation (Sue et al., 2008) . MEFs form KLF3 null mice display enhanced ability to accumulate lipid compared to wild-type ones (Sue et al., 2008) .
It is well known that KLF3 suppresses transcription by recruiting the corepressor protein CtBP (Turner and Crossley, 1998) , a cellular protein which binds to a Pro-X-Asp-Leu-Ser (PXDLS) motif. Forced overexpression of KLF3 suppresses 3T3L1 preadipocyte differentiation, while mutant PXDLS prevents CtBP binding to KLF3 exhibits no blocking effect on adipogenesis, suggesting that CtBP recruitment is required for KLF3 in regulating adipocyte differentiation (Sue et al., 2008) . MEFs from either CtBP deficient or KLF3 deficient mice exhibit eleveated expression of C/EBPa. Higher level of C/EBPa is also found in KLF3 Knocking down cells. Experimentation with 3T3L1 preadipocytes shows that KLF3 can directly bind to the endogenous C/EBPa promoter and repress its activity.
KLF7
KLF7 is originally identified by a degenerative PCR approach using a cDNA library from human vascular endothelial cells (Matsumoto et al., 1998) . Due to its expression in wide variety of human tissues, KLF7 was named the ubiquitous kruppel-like factor (UKLF), although it is known to be predominantly expressed in the brain and the spinal cord in humans, and in the central and peripheral nervous system during embryogenesis in mice (Matsumoto et al., 1998) . KLF7 is also identified as a transcriptional activator and is shown to be capable of increasing p21 WAF1/Cip1 expression (Laub et al., 2001) .
The KLF7 protein is abundant in 3T3-L1 preadipocytes. It dramatically decreases at 24hrs upon adipogenic stimulation, and gradually increases afterwards until it restores its level of preadipocytes at day 7 of differentiation (Cho et al., 2007; Kanazawa et al., 2005; Kawamura et al., 2006) . Differentiation of the human preadipocytes is remarkably inhibited by KLF7 overexpression (Cho et al., 2007; Kanazawa et al., 2005; Kawamura et al., 2006) . PPARg, C/EBPa, aP2, and adipsin decrease significantly in KLF7 overexpressing cells, whereas C/EBPb and C/EBPd are not affected (Kawamura et al., 2006) . In addition to altering adipogenic modulations, KLF7 also exerts regulatory roles in insulin sensitivity. Overexpressing KLF7 in human adipocyte decreases leptin and adiponectin levels and increases IL6 production, while overexpressing KLF7 in HIT-T15 (insulin secreting cell line) cells suppresses insulin secretion and glucose transport 2(GLUT2), pancreatic duodenal homeobox factor 1 expressions (Kawamura et al., 2006) . However, the precise role of KLF7 in the pathogenesis of type 2 diabetes through insulin regulation requires further study.
KLFs in brown adipocytes
Brown adipocytes (Cannon and Nedergaard, 2004) , which are multilocular lipid storage cells containing a large amount of mitochondria, are grouped in brown adipose tissue (BAT) depots. BAT are particularly found in the interscapular, subscapular, axillary and intercostal regions of small mammals as well as human and other large mammalian newborns. The main function of brown adipocytes is in non-shivering thermogenesis in large mammals after birth. Brown adipocytes are innervated by sympathetic nervous system (SNS) nerve endings, which release noradrenaline (NA) to stimulate brown adipocytes and uncoupling protein 1(UCP1) (Gesta et al., 2007; Nedergaard et al., 2005) . UCP1 is a unique factor of brown adipocytes to generate heat, located in the mitochondrion and UCP1, induced or repressed by factors such as cold, diet, leptin, corticosterone and obesity (Sell et al., 2004) . Several growth factors and transcription factors, including BMP-7 (Tseng et al., 2008) , PRDM16 (Seale et al., 2007) , and PGC-1a (Puigserver et al., 1998) have been suggested to have central roles in brown adipocyte differentiation and UCP1 regulation. CRE (cAMP response element), TRE/RARE (thyroid hormone response element/retinoic acid response element), and PPRE (PPAR response element) also have been reported to control UCP1 gene expression.
Kruppel-like factors containing KLF11 and KLF15 have recently been identified to be involved in UCP1 regulation (Klingenspor, 2003) , with especially KLF11 mainly expressed in pancreatic b cells and associated with type 2 diabetes (Neve et al., 2005) . Expression of KLF11 and KLF15 is rapidly induced and remains at high levels through brown adipocyte differentiation of muBM3.1 cells (Yamamoto et al., 2010) . Forced expression of KLF11, but not KLF15, in muBM3.1 cells induces UCP1 expression at an appreciable level during brown adipogenic differentiation (Yamamoto et al., 2010) . Conversely, siRNA knockdown KLF11 completely abolishes UCP1 protein expression in differentiating muBM3.1 cells, whereas muBM3.1 cells transfected with siRNAs for KLF15 has partial inhibitory effect on UPC1 (Yamamoto et al., 2010) . Study also demonstrated that KLF11 and KLF15 activate the UCP1 promoter via directly binding to its region Sp1RE-2 and Sp1RE-4, respectively (Yamamoto et al., 2010) . Cooperative action of KLF11 and KLF15 on the UCP1 promoter is essential for UCP1 induction in the process of brown adipogenic differentiation. However, KLF11 and/or KLF15 can not initiate brown adipocyte differentiation, suggesting that activation of KLF11 and/or KLF15 is necessary but not sufficient to induce brown adipocyte adipogenesis.
Roles and relationships among members of KLF family during adipogenesis
Currently, a total of 8 members in KLF family have been found to be involved in adipogenesis, and they express sequentially in the process of adipocyte differentiation (showed in Fig. 1 ). KLF2, KLF3 and KLF7 are first expressed in 3T3-L1 preadipocytes at high level, and the amounts of these three proteins decrease rapidly after hormonal cocktail stimulation. The three of KLFs play a role in the negative regulation of adipogenesis, although the mechanisms are different and their down-regulation following differentiation is an early and necessary event in the phenotypic conversion to fat cells. KLF2 in preadipocytes exerts its inhibition on PPARg expression through directly binding to the promoter of PPARg within the 0.6-kb upstream region (Banerjee et al., 2003; Wu et al., 2005) , whereas KLF3 is directly associated with C/EBPa promoter by recruiting its corepressor protein CtBP (Sue et al., 2008) . KLF7 down-regulate the expression of both PPARg and C/EBPa, although little is known about the mechanism.
In the early phase of adipocyte differentiation, KLF4, KLF5 and KLF6 are detected at about 30 min to 1 h after initiation. KLF6 is the only repressor that promotes adipogenesis by inhibiting DLK1 expression (Li et al., 2005 ). KLF4 appears to contribute to adipocyte differentiation by stimulating the expression of C/EBPb and C/EBPd together with the previously described transcription factor Krox20 (Birsoy et al., 2008) . KLF5 induces PPARg expression in coordination with C/EBPb and C/EBPd at an early phase of differentiation (Oishi et al., 2005) .
KLF9 mRNA significantly increases from day 4 of the differentiation and reaches the maximum at day 7 during the middle and late phases of adipogenesis. KLF9 activates PPARg via directly binding to À 304 bp and À 119 bp regions of the PPARg2 promoter, and the transactivation effects is enhanced in concert with C/EBPa (Pei et al., 2010) . KLF15 also appears in 3T3-L1 cells 4 days after the hormone induction, and its abundance is increased maximally from Day 6 to Day 8. KLF15 is induced by C/EBPb, C/EBPd, and GR, and plays a role similar to KLF9 in adipocyte differentiation but exerts much stronger effects (Mori et al., 2005) . KLF15 also modulates adipogenic specific genes such as GLUT4 and AceCS2, which are involved in energy metabolism in mature adipocytes. KLF9 and KLF15 are likely to sustain PPARg level in adipogenesis, although C/EBPb and C/EBPd decrease on day 4. In addition, KLF15 and KLF9 act synergistically with C/EBPa to activate PPARg promoters and maintain the expression of PPARg in the differentiated state of 3T3-L1 cells.
Collectively, there are four members in KLF family involved in adipocyte differentiation by regulating PPARg2 transcription. KLF2 is expressed in 3T3-L1 preadipocytes, and its expression is shut down upon differentiation. KLF5 is induced 4hrs after stimulation, and its expression peak occurs at the early stage of adipogenesis. KLF9 appears at the middle phase of differentiation and gradually increases throughout the middle and late stages. The expression pattern of KLF15 is similar to that of KLF9 and reaches its highest level in mature adipocytes. Although the time frame for each KLF binding to PPARg is different, they bind to the same DNA elements, within the 0.6-kb PPARg2 upstream promoter region, except for KLF15, whose binding target on the PPARg2 promoter has not been identified.
Five KLFs members have been identified to date to interact with C/EBPs. KLF3 associates with C/EBPa promoter directly by recruiting its corepressor protein CtBP in 3T3-L1 preadipocyte. KLF4 induces C/EBPb and C/EBPd with Krox20 to promote adipogenesis at the early stage. KLF5, in concert with C/EBPb and C/EBPd, transactivates the expression of PPARg and C/EBPa. And finally, KLF9 and KLF15 appear at the middle stage of differentiation lasting throughout the late stage of adipogenesis, acting together with C/EBPa via directly binding to its promoter to activate PPARg activity. These KLFs are expressed sequentially during adipogenesis and, importantly, at least one KLF member's expression corresponds to C/EBPs at each stage in adipocyte differentiation.
Future directions
The KLFs emerging during adipocyte differentiation show an important role in regulating this process. Due to similarity in their recognition sequences (including GC-and CACCC-boxes of DNA) and their similar expression patterns in adipogenesis, further investigation is needed to explore the interaction between different KLFs as a network. Is it possible that KLF6 could abrogate the activation effect of KLF2 on DLK1? Do KLFs in regulating PPARg or C/EBPa promoter activity in adipogenesis have spatiotemporal expression or inner interaction? Moreover, the precise mechanism of expression of KLFs regulating adipocyte differentiation is still elusive.
KLFs play an essential role in adipogenesis. Understanding the upstream factors that modulate KLFs expression will become necessary in fat biology, which will provide new insights for use against the growing prevalence of obesity in the modern world. Cofactors are usually required for transcription factor regulation. However, only a few interacting with KLFs have been reported, making it an important focus in future KLFs research.
Finally, the roles of KLFs in adipogenesis discussed above are mainly based on animal and cell culture studies. Data from human adipose tissue or from population-based epidemiology studies will better address the roles of KLFs in developing obesity. In conclusion, this review revealed an essential role of KLFs in the complex regulation of gene transcription during adipogenesis and their relationships in this process, although new activities await discovery. Strategies for development of targeted therapies for obesity-related diseases will arise as we continue to expand our understanding of the adipogenic functions of KLFs and their contribution to obesity.
